Excitatory and Inhibitory Brain Metabolites as Targets of Motor Cortex Transcranial Direct Current Stimulation Therapy and Predictors of Its Efficacy in Fibromyalgia

Bradley R. Foerster, 1 Thiago D. Nascimento, 2 Misty DeBoer, 2 Mary-Catherine A. Bender, 2 Indie C. Rice, 2 Dennis Q. Truong, 3 Marom Bikson, 3 Daniel J. Clauw, 2 Jon-Kar Zubieta, 2 Richard E. Harris, 2 and Alexandre F. DaSilva 2

Objective. Transcranial direct current stimulation (tDCS) has been shown to improve pain symptoms in fibromyalgia (FM), a central pain syndrome whose underlying mechanisms are not well understood. This study was undertaken to explore the neurochemical action of tDCS in the brain of patients with FM, using proton magnetic resonance spectroscopy ( 1 H-MRS).

ClinicalTrials.gov identifier: NCT01745003.

Supported by an NIH Clinical and Translational Science Award program high-tech funding grant to the Michigan Institute for Clinical and Health Research Clinical Trial Planning Program, University of Michigan. The application and processing tools used in this study were developed under NIH grants P41-EB-015909 and R01-EB-016089.

1 Bradley R. Foerster, MD, PhD: University of Michigan and Ann Arbor VA Healthcare System, Ann Arbor, Michigan, and Johns Hopkins University, Baltimore, Maryland; 2 Thiago D. Nascimento, DDS, MSc, Misty DeBoer, BS, Mary-Catherine A. Bender, BS, Indie C. Rice, IP, Daniel J. Clauw, MD, Jon-Kar Zubieta, MD, PhD, Richard E. Harris, PhD, Alexandre F. DaSilva, DDS, DMD, ScD, University of Michigan, Ann Arbor; 3 Dennis Q. Truong, PhD, Marom Bikson, PhD: City University of New York, New York, New York.

The present findings suggest that GABA, Glx, and NAA play an important role in the pathophysiology of FM and its modulation by tDCS.
unresolved pain and disability. A significant limitation to evaluating potential interventions for chronic pain syndromes, including FM, is the lack of an objective marker of pain. There has been significant interest in using neuroimaging methods, such as proton magnetic resonance spectroscopy (1H-MRS), to develop an objective test of pain. 1H-MRS can be used to measure levels of brain metabolites, including γ-aminobutyric acid (GABA) (the brain’s major inhibitory neurotransmitter), Glx (a combined marker of glutamine and glutamate, the latter being the brain’s major excitatory neurotransmitter), and N-acetylaspartate (NAA) (thought to be a measure of neuronal integrity). Our group has reported increased levels of Glx in the posterior insula, which is responsible for the graded sensory processing of pain (5,6), in patients with FM. We have also reported decreased levels of GABA in the anterior insula, which is important in the emotional processing and affective aspects of pain (6,7), in FM patients. Lower NAA levels within the hippocampus in the setting of FM have also been described (8).

One potential treatment for FM is transcranial direct current stimulation (tDCS), a brain-stimulating procedure that uses noninvasive weak direct current applied to the scalp. In FM as well as other pain conditions, tDCS has been shown to modulate experimental and clinical pain. Specifically, it has been found to improve pain symptoms in FM (9,10). Anodal stimulation from tDCS has been demonstrated to increase cortical excitability, which is postulated to mitigate pain symptoms through indirect effects on pain processing regions in the brain (9). However, the mechanisms underlying the efficacy of tDCS in chronic pain are not well understood, and trials assessing its effects on chronic pain have yielded inconsistent results (11). Our objective in the present study was to explore the underlying neurochemical action of tDCS in the brain in FM, using 1H-MRS.

PATIENTS AND METHODS

Trial design. This longitudinal trial had 3 phases: 1) a baseline period to measure pain levels and perform 1H-MRS, 2) 5 consecutive days of sham tDCS, followed by pain assessment and 1H-MRS, and 3) 5 consecutive days of active tDCS, followed by pain assessment and 1H-MRS. The second and third phases were separated by a 7-day washout period. Randomization was not performed given the presence of significant carryover effects with active tDCS (12) and the small sample size.

Patients. Thirteen female subjects (mean ± SD age 47.6 ± 10.6 years [range 27–64]) were recruited for this study. Twelve of the subjects completed the entire protocol; 1 dropped out after the baseline pain assessment/1H-MRS. The first 2 of the 12 subjects did not have GABA data collected at the baseline time point due to protocol change, but did have Glx and NAA data collected. All subjects met the American College of Rheumatology 1990 criteria for FM (13) with a symptom duration of at least 1 year, had reported continued presence of pain on >50% of days, and were willing to refrain from introducing any new medications or treatments for control of FM symptoms during the study. All subjects were right-handed and had a body mass index of ≤36 kg/m². We excluded FM patients who had a history of coexisting autoimmune or chronic inflammatory disease that causes pain (e.g., rheumatoid arthritis, systemic lupus erythematosus, or inflammatory bowel disease), who had a history of substance abuse or were currently taking opiates, or who had a history of severe psychiatric illness (e.g., current major depression and schizophrenia). FM patients who were pregnant, breastfeeding, or participating in other therapeutic clinical trials were also excluded. The study was approved by the University of Michigan Institutional Review Board. All subjects provided written informed written consent.

Clinical assessments. In clinical assessments, the patients were asked to refer to the “average” symptoms experienced/perceived during 3 time periods: the week prior to the initial 1H-MRS, the period between first-trial initiation (sham tDCS) and second 1H-MRS, and the period between second-trial initiation (active tDCS) and final 1H-MRS. Pain intensity was measured using a 10-point visual analog scale (VAS), with 0 representing no pain and 10 representing the worst possible pain. Affective state was assessed using the positive and negative affect scores from the Positive and Negative Affect Schedule (PANAS) (14). Pain discrimination and subjective pain experience were evaluated using the long-form McGill Pain Questionnaire (15) for the baseline visit and the short-form McGill Pain Questionnaire (16) for the post–sham tDCS and post–active tDCS visits.

Transcranial direct current stimulation. For both the sham and active tDCS sessions, the anode electrode was placed on the scalp overlying the left motor cortex and the cathode electrode was placed on the scalp overlying the right supraorbital cortex. During the active tDCS sessions, 2 mA of transcranial direct current stimulation was applied for 20 minutes. For the sham tDCS, the current was applied for only 30 seconds at the beginning and end of the session. A 30-second application of current is considered a method of sham stimulation, as sensations arising from tDCS treatment occur mostly at the beginning and end of application (17). Individual measurements determined the anatomic location for placement of the electrodes using the convention of electroencephalography 10/20 system. Placement of the electrodes was performed by the same operators (AFD and TDN) for all patients.

Proton magnetic resonance spectroscopy. A Philips Ingenia 3T system with a 15-channel receive head coil was used for imaging acquisition. Voxel placement was performed using a 3-dimensional magnetization-prepared rapid gradient-echo sequence with 0.9-mm³ isotropic voxel resolution. 1H-MRS spectra were collected with 3.0 cm × 2.0 cm × 3.0 cm volumes from the right anterior insula, right posterior insula, and anterior cingulate and a 2.0 cm × 4.0 cm × 2.2 cm volume from bilateral thalami (data available from the corresponding au-
The experiment was performed using the following parameters: TE (repetition time [TR]/echo time [TE] 2,000/35 msec) was performed to measure GABA levels. The MEGA-PRESS (selective editing pulses (14 msec) applied at 1.9 ppm (on) and 7.46 ppm (off). Amplitude-modulated pulse GTST1203 (length 7 msec, bandwidth 1.2 kHz) was used for refocusing.

Conventional PRESS spectroscopy data were analyzed with LCModel. MEGA-PRESS spectroscopy data were analyzed using MatLab in-house postprocessing software to fit Gaussian curves to the GABA and inverted NAA peaks. The absolute NAA concentration, as generated from the MatLab analysis to determine the concentration of GABA (in arbitrary institutional units [AIU]). There was inadequate signal-to-noise ratio for the GABA spectra in the anterior cingulate and anterior insula in 1–2 subjects, and in the thalami in 2–3 subjects, at each of the trial phases.

Single-voxel point-resolved spectroscopy (PRESS) (repetition time [TR]/echo time [TE] 2,000/35 msec) was performed using VAPOR (variable pulse power and optimized relaxation) water suppression with 32 averages to measure Glx and NAA levels. A Mescher-Garwood point-resolved spectroscopy (MEGA-PRESS) experiment, which edits out the overlapping creatine peak at 3.0 parts per million (19), was performed using the following parameters: TE (15 msec, TE2 53 msec), TR 1.8 seconds, 256 transients of 2,000 data points, spectral width 2 kHz, frequency selective editing pulses (14 msec) applied at 1.9 ppm (on) and 7.46 ppm (off). Amplitude-modulated pulse GTST1203 (length 7 msec, bandwidth 1.2 kHz) was used for refocusing.

Results

We observed substantial longitudinal changes in clinical pain scores, with a significant decrease in the VAS pain score from baseline to active tDCS (P = 0.04) (Table 1). There was a trend toward a decrease in the

<table>
<thead>
<tr>
<th>VAS pain score</th>
<th>Baseline</th>
<th>Post–sham tDCS</th>
<th>Post–active tDCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean ± SD</td>
<td>5.1 ± 2.3</td>
<td>4.1 ± 2.1</td>
<td>3.3 ± 2.8†</td>
</tr>
<tr>
<td>Correlation (r)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– With ACC GABA level</td>
<td>−0.74§</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>– With post. ins. NAA level</td>
<td>NS</td>
<td>NS</td>
<td>−0.60§</td>
</tr>
<tr>
<td>– With thalamus GABA level</td>
<td>−0.75§</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>– With thalamus NAA level</td>
<td>NS</td>
<td>−0.75‡</td>
<td>NS</td>
</tr>
<tr>
<td>MPQ score (long form), mean ± SEM</td>
<td>22.9 ± 14.9</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>MPQ score (short form), mean ± SEM</td>
<td>–</td>
<td>18.7 ± 12.5</td>
<td>19.3 ± 15.3</td>
</tr>
<tr>
<td>PANAS+ score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>19.8 ± 6.0</td>
<td>17.8 ± 5.5</td>
<td>16.1 ± 6.4</td>
</tr>
<tr>
<td>Correlation (r)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– With ant. ins. Glx level</td>
<td>−0.87‡</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>– With ant. ins. NAA level</td>
<td>−0.68§</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>– With ant. ins. GABA level</td>
<td>NS</td>
<td>NS</td>
<td>0.71§</td>
</tr>
<tr>
<td>– With post. ins. Glx level</td>
<td>−0.78§</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>– With post. ins. NAA level</td>
<td>NS</td>
<td>NS</td>
<td>0.61§</td>
</tr>
<tr>
<td>– With thalamus GABA level</td>
<td>NS</td>
<td>−0.78§</td>
<td>NS</td>
</tr>
<tr>
<td>PANAS– score</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean ± SD</td>
<td>14.3 ± 3.4</td>
<td>15.4 ± 5.5</td>
<td>12.7 ± 3.6‡</td>
</tr>
<tr>
<td>Correlation (r)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>– With post. ins. GABA level</td>
<td>NS</td>
<td>NS</td>
<td>−0.65§</td>
</tr>
<tr>
<td>– With post. ins. NAA level</td>
<td>NS</td>
<td>NS</td>
<td>−0.63§</td>
</tr>
<tr>
<td>– With thalamus GABA level</td>
<td>NS</td>
<td>−0.79‡</td>
<td>NS</td>
</tr>
</tbody>
</table>

* tDCS = transcranial direct current stimulation; VAS = visual analog scale; ACC = anterior cingulate; GABA = γ-aminobutyric acid; NS = not significant; post. ins. = posterior insula; NAA = N-acetylaspartate; MPQ = McGill Pain Questionnaire; PANAS = Positive and Negative Affect Schedule; ant. ins. = anterior insula; Glx = combined glutamate + glutamine.

† P = 0.04 versus baseline.
‡ P = 0.01.
§ P = 0.05.
¶ P = 0.02 versus baseline.
VAS score from baseline to sham tDCS ($P = 0.10$). Between sham tDCS and active tDCS the VAS pain score did not change significantly ($P = 0.16$). The PANAS score decreased significantly from baseline to active tDCS ($P = 0.02$). There were no additional significant changes in the PANAS score for the different time point comparisons. Between sham tDCS and active tDCS there was a significant decrease in Glx levels in the anterior cingulate ($P = 0.013$) and a trend toward a decrease in Glx levels in the thalamus ($P = 0.056$) (Figure 1). From baseline to active tDCS there was a trend toward an increase in GABA levels in the anterior insula ($P = 0.064$). In addition, NAA levels in the posterior insula increased significantly from baseline (mean $\pm$ SD 7.68 $\pm$ 0.45 AIU) to sham tDCS (8.24 $\pm$ 0.58 AIU) ($P = 0.015$).

There were a number of moderate-to-strong correlations between brain metabolite levels and the clinical rating scales. Higher levels of GABA and NAA and lower levels of Glx from the prescribed brain region voxels were associated with better clinical pain and affect scores (Table 1). Linear regression analysis revealed that Glx levels in the anterior cingulate at baseline correlated significantly with changes in the VAS pain score between baseline and sham tDCS ($\beta_1 = 1.31$, $P < 0.001$) and between baseline and active tDCS ($\beta_1 = 1.87$, $P < 0.001$) (Figure 2), with higher levels of Glx in the anterior cingulate at baseline associated with greater reductions in clinical pain following both the sham and active treatment phases.

**DISCUSSION**

In the present longitudinal trial we observed that the anterior cingulate was the region most affected by tDCS treatment in FM patients, with a significant decrease in Glx levels. Furthermore, we found that patients with higher levels of Glx in the anterior cingulate at baseline tended to show a greater degree of improvement in clinical pain after both the sham and the tDCS treatments. The anterior cingulate is a key component in the brain’s pain modulating regions and is also involved in the emotional processing of pain (6). Its structure and function have been found to be altered in chronic pain states; specifically, focal atrophy and reduced connectivity in the rostral anterior cingulate have been described (12,18). Furthermore, the rostral anterior cingulate has been shown to be an important region for descending inhibition of pain (12). Our findings suggest that “normalization” of Glx in the anterior cingulate may have an important role in the mechanism of action of tDCS for the treatment of fibromyalgia. In addition, the strength of the regression coefficient and high level of significance between Glx levels in the anterior cingulate and
clinical pain improvement suggest that $^{1}$H-MRS may prove to be a clinically useful predictor of tDCS efficacy in FM. We speculate that the higher regression coefficient for the correlation of baseline Glx levels with the change in pain score after active tDCS ($\beta_1 = 1.87$) relative to the change in pain score after sham tDCS ($\beta_1 = 1.31$) may reflect additive placebo response to the tDCS treatment.

The present findings complement our results in a study of pregabalin treatment, which demonstrated that baseline Glx levels were associated with pain response, albeit in a different brain region (3). Increases in Glx and NAA levels following tDCS stimulation have been observed in the parietal cortex underneath the anode (20), suggesting that tDCS locally increases glutamatergic activity and neuronal metabolism.

There was a trend toward decreased levels of Glx in the thalamus following tDCS treatment. The thalamus, which is a critical pain relay and processing center, has exhibited alterations in blood flow, white matter structure, and connectivity in FM (21). We also observed a trend toward increased levels of GABA in the anterior insula following tDCS treatment, complementing our earlier findings of reduced levels of GABA in FM patients as compared to healthy controls (7). The pain processing regions of the brain also demonstrated significant correlations between GABA and Glx levels and clinical pain scores: patients with higher levels of GABA and lower levels of Glx had lower levels of pain intensity (as measured by VAS) and negative affect (as measured by PANAS$^-$) and higher levels of positive affect (as measured by PANAS$^+$). These findings are consistent with the notion that in FM there is an excitatory: inhibitory ratio imbalance in the brain, resulting in up-regulation of pain response/experience, as we have previously proposed (5,7). Similar results were demonstrated with regard to NAA levels in the anterior insula, posterior insula, and thalamus: patients with lower pain scores, lower levels of negative affect, and higher levels of positive affect tended to have higher levels of NAA.

Our findings, in addition to the increase in NAA levels in the posterior insula that we observed following sham tDCS treatment, suggest that neuronal integrity, as measured by NAA, is important in chronic pain.

Limitations of the present study include the relatively small number of subjects and lack of randomization. The large number of statistical comparisons raises the possibility of Type I error. Furthermore, we were unable to demonstrate a significant improvement in clinical pain scores between the sham tDCS and active tDCS time points, which may be due in part to placebo response and the small sample size. We suggest that given the exploratory nature of this study, subsequent efforts be undertaken to confirm our results. In addition, the GABA editing acquisition includes contributions from macromolecules. GABA editing requires relatively large voxel sizes and long time acquisitions, limiting the number of potential brain regions to interrogate. For future pain studies, it would be interesting to measure local $^{1}$H-MRS changes underneath the anode.

In conclusion, our findings suggest that GABA, Glx, and NAA play important roles in the pathophysiology of chronic pain and its modulation by tDCS. There were significant alterations in the levels of metabolites...
for various pain centers in the brain following both the sham and active tDCS phases of the present trial. Furthermore, baseline Glx levels in the anterior cingulate predicted response to treatment. These findings encourage further work to pursue targeted therapy with tDCS and other noninvasive brain stimulation modalities in FM and other chronic pain conditions.

ACKNOWLEDGMENT

The authors are grateful to Dr. Richard Edden for assistance with data acquisition and postprocessing.

AUTHOR CONTRIBUTIONS

All authors were involved in drafting the article or revising it critically for important intellectual content, and all authors approved the final version to be published. Dr. Foerster had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study conception and design. Clauw, Zubieta, Harris, DaSilva.

Acquisition of data. Foerster, Nascimento, DeBoer, Bender, Rice, DaSilva.

Analysis and interpretation of data. Foerster, Nascimento, DeBoer, Rice, Truong, Bikson, Zubieta, Harris, DaSilva.

REFERENCES